Drug-drug interaction potential of SH-1028, a third-generation EGFR-TKI: in vitro and clinical trials [0.03%]
SH-1028（第三代EGFR-TKI）药物相互作用的体外和临床试验研究
Xiaoli Li,Yuyan Liu,Minhui Zhu et al.
Xiaoli Li et al.
SH-1028 is an irreversible third-generation EGFR tyrosine kinase inhibitor (EGFR-TKI) for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC). Considering the possibility of combination therapy in patients wit...
Liquid biopsy using cell-free DNA in the early diagnosis of hepatocellular carcinoma [0.03%]
基于游离DNA的液体活检技术在肝细胞癌早期诊断中的应用研究进展
Shiqi Hu,Yaqin Liu,Qidong Yang et al.
Shiqi Hu et al.
Hepatocellular carcinoma ranks fourth in cancer-related causes of death worldwide and second in China. Patients with hepatocellular carcinoma (HCC) at the early stage have a better prognosis compared to HCC patients at the late stage. There...
A phase I/II study of MCS110 with BRAF/MEK inhibition in patients with melanoma after progression on BRAF/MEK inhibition [0.03%]
MCS110与BRAF/MEK抑制药联合治疗BRAF/MEK抑制药进展后黑色素瘤患者的I/II期临床试验
Elizabeth I Buchbinder,Anita Giobbie-Hurder,Patrick A Ott
Elizabeth I Buchbinder
Background: Prognosis for patients with metastatic melanoma has been improved dramatically with the development of BRAF/MEK directed therapy and immune checkpoint inhibition. However, resistance to therapy remains a chall...
Dasatinib in combination with BMS-754807 induce synergistic cytotoxicity in lung cancer cells through inhibiting lung cancer cell growth, and inducing autophagy as well as cell cycle arrest at the G1 phase [0.03%]
Dasatinib联合BMS-754807通过抑制肺癌细胞生长、诱导自噬以及G1期细胞周期停滞在肺癌细胞中产生协同毒性作用
Chan Zhang,Xinan Zhao,Zifeng Wang et al.
Chan Zhang et al.
Lung cancer is the leading cause of cancer-related deaths worldwide. Combination of drugs targeting independent signaling pathways would effectively block the proliferation of cancer cells with lower concentrations and stronger synergy effe...
Efficacy of salvage therapies after failure of adjuvant anti-PD-1 monotherapy for melanoma in the Chinese population: a multi-institutional cohort study [0.03%]
中国人群黑色素瘤辅助抗PD-1单药治疗失败后的补救疗法疗效：一项多机构队列研究
Dong-Dong Jia,Yu Xu,Ting Li et al.
Dong-Dong Jia et al.
The majority of melanoma patients experience relapse during adjuvant therapy or after the end of therapy. Sixty-one patients from 3 melanoma centres who experienced recurrence and received adjuvant pembrolizumab for resected stage III/IV me...
Multicenter Study
Investigational new drugs. 2023 Jun;41(3):431-437. DOI:10.1007/s10637-023-01348-5 2023
A dose escalation/expansion study evaluating dose, safety, and efficacy of the novel tyrosine kinase inhibitor surufatinib, which inhibits VEGFR 1, 2, & 3, FGFR 1, and CSF1R, in US patients with neuroendocrine tumors [0.03%]
评价瑞普替尼在美国神经内分泌肿瘤患者中的剂量、安全性和有效性的剂量递增/扩展研究：一项Ib期试验
Arvind Dasari,Erika P Hamilton,Gerald S Falchook et al.
Arvind Dasari et al.
Surufatinib, is a potent inhibitor of vascular endothelial growth factor receptors 1-3; fibroblast growth factor receptor-1; colony-stimulating factor 1 receptor. This Phase 1/1b escalation/expansion study in US patients with solid tumors e...
Soluble interleukin-2 receptor as a predictive biomarker for poor efficacy of combination treatment with anti-PD-1/PD-L1 antibodies and chemotherapy in non-small cell lung cancer patients [0.03%]
可溶性IL-2受体作为预测非小细胞肺癌患者抗PD-1/PD-L1抗体联合化疗疗效不佳的生物标志物
Takehiro Tozuka,Noriko Yanagitani,Hiroshi Yoshida et al.
Takehiro Tozuka et al.
Soluble interleukin-2 receptor (sIL-2R) suppresses effector T-cells. Few studies have assessed serum sIL-2R in patients receiving immunotherapy. We evaluated the association between serum sIL-2R levels and the efficacy of anti-programmed ce...
Brigatinib pharmacokinetics in patients with chronic hepatic impairment [0.03%]
brigatinib在慢性肝功能不全患者中的药代动力学研究
Michael J Hanley,David Kerstein,Meera Tugnait et al.
Michael J Hanley et al.
Brigatinib is an anaplastic lymphoma kinase (ALK) inhibitor approved for the treatment of ALK-positive non-small cell lung cancer. This open-label, parallel-group study investigated the effect of chronic hepatic impairment on the pharmacoki...
Targeting chemotherapy resistance in mesenchymal triple-negative breast cancer: a phase II trial of neoadjuvant angiogenic and mTOR inhibition with chemotherapy [0.03%]
针对间质型三阴性乳腺癌的新辅助化疗耐药治疗：一项抑制血管生成和mTOR的Ⅱ期临床试验
Nour Abuhadra,Ryan Sun,Roland L Bassett Jr et al.
Nour Abuhadra et al.
Results of an open-label phase 1b study of the ERK inhibitor MK-8353 plus the MEK inhibitor selumetinib in patients with advanced or metastatic solid tumors [0.03%]
一项Ib期开放标签研究结果：ERK抑制剂MK-8353与MEK抑制剂司美替尼联用治疗晚期或转移性实体瘤患者的效果
Anastasios Stathis,Anthony W Tolcher,Judy S Wang et al.
Anastasios Stathis et al.
Aim: We evaluated MK-8353 (small molecule inhibitor of extracellular signal-regulated kinase 1/2) plus selumetinib (mitogen-activated extracellular signal-regulated kinase 1/2 inhibitor) in patients with advanced solid tu...